C‐peptide and diabetic kidney disease

Brunskill, Nigel

doi:10.1111/joim.12548

Cited by 32 publications

(31 citation statements)

References 95 publications

(110 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CP has emerged as an effective treatment for DN (8)(9)(10)(11)(12)(13)32). Several mechanisms have been reported for the protective effects of CP (14).…”

Section: Discussionmentioning

confidence: 99%

C‐peptide prevents NF‐κB from recruiting p300 and binding to the inos promoter in diabetic nephropathy

et al. 2018

FASEB j.

View full text Add to dashboard Cite

C-peptide (CP) has demonstrated unique beneficial effects in diabetic nephropathy (DN), but whether and how CP regulates NF-κB and its coactivator, p300, to suppress inducible iNOS and antagonize DN are unknown. iNOS expression, NF-κB nuclear translocation, colocalization and binding of NF-κB to p300, binding of NF-κB to the inos promoter, and the bound NF-κB, p300, and histone 3 lysine 9 acetylation (H3K9ac) at binding sites were measured in high glucose-stimulated mesangial cells. We evaluated pathologic changes, iNOS expression, NF-κB, and p300 contents in diabetic rats. We found that CP inhibited iNOS expression and notably prevented colocalization and binding of NF-κB and p300. CP prevented NF-κB from binding to the inos promoter, especially at the distal site, and reduced bound NF-κB, p300, and H3K9ac. N-terminal plus middle fragment could mostly mimic the antagonizing effects of CP against the pathologic changes of DN and equally suppresses renal iNOS expression as CP. In conclusion, CP prevented NF-κB from recruiting p300 and binding to the inos promoter, and decreased H3K9ac at the binding sites to suppress iNOS expression and antagonize DN, with the effect region identified as N-terminal plus middle fragment.-Li, Y., Li, X., He, K., Li, B., Liu, K., Qi, J., Wang, H., Wang, Y., Luo, W. C-peptide prevents NF-κB from recruiting p300 and binding to the inos promoter in diabetic nephropathy.

show abstract

“…CP has emerged as an effective treatment for DN (8)(9)(10)(11)(12)(13)32). Several mechanisms have been reported for the protective effects of CP (14).…”

Section: Discussionmentioning

confidence: 99%

C‐peptide prevents NF‐κB from recruiting p300 and binding to the inos promoter in diabetic nephropathy

et al. 2018

FASEB j.

View full text Add to dashboard Cite

show abstract

“…Poza rolą C-peptydu jako markera funkcji komórek beta w cukrzycy typu 1 diabetolodzy zaczęli doszukiwać się dodatkowej roli C-peptydu jako substancji biologicznie czynnej mającej znaczenie plejotropowe [6][7][8] m.in. w prewencji powikłań naczyniowych, nerkowych [9][10][11] jak i możliwości stosowania terapeutycznego razem z insuliną [12,13].…”

Section: Wstępunclassified

C-peptide level and clinical parameters in children with new onset type 1 diabetes

Szewczyk¹,

Pierpoint²,

Bury³

2017

Pediatr. Endocrinol.

View full text Add to dashboard Cite

Słowa kluczowe cukrzyca typu1, C-peptyd, HbA1c, kwasica, zapotrzebowanie na insulinę. Streszczenie Ostatnie doniesienia wskazują na plejotropowe znaczenie C-peptydu w cukrzycy typu 1. Materiał i metody. Badania dotyczą 47 dzieci w wieku 1-16 lat z nowo rozpoznaną cukrzycą typu 1. Oceniano u nich poziom C-peptydu (met. elektrochemiluminescencji) w relacji do wartości HbA1c, pH krwi oraz zapotrzebowania na insulinę po uzyskaniu wyrównania metabolicznego. Wyniki. Wszystkie dzieci miały obniżone poziomy C-peptydu (M=0,57+0,29 ng/ml), podwyższone wartości HbA1c (M=12,27 + 2,44%), część (28%) miała pH krwi <7,3 oraz prawie wszystkie wymagały po wyrównaniu stosowania remisyjnych dawek insuliny (M= 0,38+0,29 j/kg). Uzyskano tylko pozytywną korelację pomiędzy poziomami C-peptydu a pH krwi po przyjęciu do kliniki.

show abstract

“…The combined evidence from in vivo animal observations and clinical studies in patients with type 1 diabetes indicates a potential role for C‐peptide in the treatment of diabetes‐induced functional and structural abnormalities of the kidneys. In an overview of C‐peptide and diabetic nephropathy this issue of the Journal, a putative therapeutic role for C‐peptide is discussed, together with the possible mechanisms involved and the need for further studies in patients .…”

Section: Renal Function and C‐peptidementioning

confidence: 99%

C‐peptide and the pathophysiology of microvascular complications of diabetes

Wahren

2016

J Intern Med

View full text Add to dashboard Cite

show abstract

C‐peptide and diabetic kidney disease

Abstract: Content List -Read more articles from the symposium: C-peptide and the pathogenesis of microvascular complications of diabetes.Abstract. Brunskill NJ

Cited by 32 publications

References 95 publications

C‐peptide prevents NF‐κB from recruiting p300 and binding to the inos promoter in diabetic nephropathy

C‐peptide prevents NF‐κB from recruiting p300 and binding to the inos promoter in diabetic nephropathy

C-peptide level and clinical parameters in children with new onset type 1 diabetes

C‐peptide and the pathophysiology of microvascular complications of diabetes

Contact Info

Product

Resources

About